Nearly half of people diagnosed with advanced cancer over a recent 5-year period did not undergo next-generation sequencing, according to results of a retrospective cohort study.Rates improved over ...

"In our study, we showed that fine needle aspiration (FNA) biopsy material can be a good source for next-generation sequencing (NGS) for patients with metastatic prostate cancer. Based on these ...

Please provide your email address to receive an email when new articles are posted on . Real-world data show that only about 30% to 40% of patients with the most common cancers receive NGS testing.

Advances in next-generation sequencing (NGS) and synthetic DNA technologies are reshaping oncology research by enabling earlier cancer detection, more accurate biomarker discovery, and sensitive ...

In this cohort study, most patients with advanced or metastatic cancers did not undergo tumor genomic testing. Low socioeconomic status, Black race or Hispanic ethnicity, and Medicaid or Medicare ...

Next-generation sequencing (NGS) is recommended for patients with metastatic prostate cancer (PC). Nationwide, testing rates are low. Whether PC disease characteristics and courses differ between ...

Mount Sinai Health System, based in New York City, will adopt an artificial intelligence-powered platform from SOPHiA GENETICS to expand its cancer research and genomic testing capabilities. The ...

PacBio PACB recently announced a new joint workflow with Covaris, a PerkinElmer company and leader in sample preparation ...

Twice the output, half the runtime, and half the footprint of the UG 100® with greater flexibility and improved genomic coverage Introducing two new high-throughput instrument configurations ...